CHLORMIDAZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H13ClN2
Molecular Weight	256.73
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(C=CC=C2)N1CC3=CC=C(Cl)C=C3

InChI

InChIKey=WNAQOLSMVPFGTE-UHFFFAOYSA-N

InChI=1S/C15H13ClN2/c1-11-17-14-4-2-3-5-15(14)18(11)10-12-6-8-13(16)9-7-12/h2-9H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C15H13ClN2
Molecular Weight	256.73
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://leki-opinie.pl/polfungicid-plyn | https://www.ncbi.nlm.nih.gov/pubmed/945306 | https://www.ncbi.nlm.nih.gov/pubmed/2395759

Chlormidazole was the first azole introduced the treatment of topical mycosis. It demonstrated inhibitory activity against many fungi and some gram-positive cocci. It is used for the treatment of fungal and bacterial infections of nails and skin, including interdigital and periungual mycoses. Possible side effects are: local skin irritation, burning, itching.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatomycosis 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/725113 https://www.ncbi.nlm.nih.gov/pubmed/129703 https://www.ncbi.nlm.nih.gov/pubmed/945306	Curative		Approved 8583	Myco-polycid Approved Use Indicated for the treatment of fungal and fungal-bacterial (mixed) skin and nail infections (including interdigital and periungual mycoses).

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153 CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 176.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 212.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 25.0	yes [IC50 10.964 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 32.0	yes [IC50 24.5454 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 13.0	yes [IC50 3.0901 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 19.0	yes [IC50 7.2343 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 21.0	yes [IC50 7.7619 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 16 \| 212	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/71821#section=Biological-Test-Results Page: 220.0

PubMed

Title	Date	PubMed
Azole antimycotics--a highway to new drugs or a dead end?	2012	22257053
[Sensitivity of aerobic bacteria and Candida species to chlormidazole hydrochloride in vitro].	1990-01-22	2395759
[Antibacterial and antifungal compounds. V. Synthesis and antimicrobial activity of N-(2-arylethylaminophenyl)-1H-pyrryl-1-amine and 1-(1H-pyrrol-1-yl)-2-arylmethylbenzimidazole)].	1985-07	4043374
Topical pharmacology of imidazole antifungals.	1976	945306
[Efficacy of the Myco-Polycid preparation in the form of tincture and cream for the treatment of dermatomycoses].	1975-12	129703
[Treatment of dermatomycoses with Myco-Polycid].	1975-05	1160933
[Clinical results in treatment of dermatomycoses with Myco-Polycid].	1973-12	4589249

Patents

Sample Use Guides

In Vivo Use Guide

2-3 times per day; Treatment should be continued for at least 4 weeks after complete elimination of discomfort.

Route of Administration: Topical

In Vitro Use Guide

Over 100 bacterial stains, including Candida sp., gram-positive cocci and some gram-negative bacilli, were tested. The majority of microorganisms was isolated from man. Only one bacterial strain (5 ug/mL) and 76% of Candida strains were sensitive to chlormidazole HCl (10 ug/mL).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:59:26 GMT 2025` Edited by `admin` on `Wed Apr 02 09:59:26 GMT 2025`
Record UNII	8IKK64FJVX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORMIDAZOLE

Official Name

English

CHLORMIDAZOLE [MI]

Preferred Name

English

Chlormidazole [WHO-DD]

Common Name

English

chlormidazole [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QD01AC04